Helping to Bring Hematologic Oncology Therapies to Cancer Patients

Catalyst Oncology is a niche oncology clinical research organization (CRO) devoting time, energy, and capital to supporting biotechs in bringing next-generation hematologic oncology (heme/onc) therapies to cancer patients. Clinical trials in hematologic malignancies are complex, more so than in solid tumors and thus require a higher level of expertise in your CRO partner. Bringing effective heme/onc therapies to proof-of-concept and then to market as fast as possible is our mission because every second counts for patients living with blood cancer and their families.

Active portfolio in a range of hematologic oncology trials

Active portfolio in a range of heme/onc trials

•  Leukemias
  • AML, CLL/SLL, CML
• Lymphomas
  • DLBCL, FL, MCL, NHL, PTCL
• Multiple Myeloma (MM)
• Myelodysplastic Syndrome (MDS)
• Rare Indications
  • AITL, PTCL, MZL

We understand the nuances of heme/onc trials

• Complex endpoints
  • (Cheson, Lugano, IMWG etc.)
• Patients with significant comorbidities
• I/E criteria, wash-out windows, rescue medications
• Competitive clinical trial landscape
• Challenging enrollment rates

Exclusively biotech-focused

Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye to rapid shifts when protocols amend or Breakthrough designations move a product straight from Phase I to registration.

Seasoned oncology experts  

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

Additional differentiators 

Active next-generation oncology experience

Working largely in early- to mid-phase development across a range of both solid and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.